Frequency and Clinical Evolution of Olfactory and Taste Disorders in COVID-19 Patients

Sponsor
Centre Hospitalier Universitaire de Nice (Other)
Overall Status
Unknown status
CT.gov ID
NCT04361565
Collaborator
(none)
50
Enrollment
1
Location
2.4
Anticipated Duration (Months)
21.1
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

A novel coronavirus SARS-CoV-2 HAS arose in 2019 in Wuhan, China. Beside the classical semiology of this infection, numerous patients described olfactory and teste disorders. These symptoms are not described in this coronavirus, neurotropism of coronaviridae has been documented before. The aim of the study is to evaluate prevalence of anosmia and dysgeusia (olfactory and taste disorders) in coronavirus diagnosed patients and compare with different clinical conditions. The second endpoint is to evaluate the duration of these symptoms in order to better understand the semiology of this infection.

Condition or DiseaseIntervention/TreatmentPhase

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    50 participants
    Observational Model:
    Case-Only
    Time Perspective:
    Retrospective
    Official Title:
    Prevalence and Clinical Evolution of Olfactory and Taste Disorders in Patients Infected by SARS-CoV-2
    Actual Study Start Date :
    Mar 20, 2020
    Actual Primary Completion Date :
    Apr 10, 2020
    Anticipated Study Completion Date :
    May 31, 2020

    Arms and Interventions

    ArmIntervention/Treatment
    Individuals diagnosed for COVID-19

    Outcome Measures

    Primary Outcome Measures

    1. Anosmia [45 days]

      Prevalence for anosmia in the COVID-19 + patients

    2. Ageusia [45 days]

      Prevalence for ageusia in the COVID-19 + patients

    3. Duration of the loss of anosmia ageusia [45 days]

      Duration measured in days

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • COVID-19 diagnosed

    Contacts and Locations

    Locations

    SiteCityStateCountryPostal Code
    1CHU de NiceNiceFrance

    Sponsors and Collaborators

    • Centre Hospitalier Universitaire de Nice

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Centre Hospitalier Universitaire de Nice
    ClinicalTrials.gov Identifier:
    NCT04361565
    Other Study ID Numbers:
    • 20odontocovid01
    First Posted:
    Apr 24, 2020
    Last Update Posted:
    May 13, 2020
    Last Verified:
    Apr 1, 2020
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of May 13, 2020